Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00778700 · ClinicalTrials.gov registry record · Phase 2
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
A Phase 2 study of Psoriasis, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
- 20
- Study locations
NCT00778700: Completed Phase 2 study of Psoriasis, sponsored by Incyte Corporation.
NCT00778700 is a Phase 2 study of Psoriasis that has completed, run by Incyte Corporation. The registered enrollment target is 199 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00778700, a Phase 2 study of Psoriasis, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive dressings. There were 4 treatment groups anticipated to have 50 participants in each.
Primary Outcome
Total Lesion Score is calculated as the sum of component scores for erythema (E), scaling (S), and thickness (T) of the study-treated lesions taken together. Each component consists of ratings of 0=none, 1=mild, 2=moderate, 3=marked, and 4=severe such that total lesion score can vary in value from 0 to 12. A negative change from Baseline indicates improvement.
Conditions Studied
Interventions
- DRUG Ruxolitinib Phosphate
- OTHER Placebo Cream
Study Locations (20)
California
- - Los Angeles
- - San Diego
- - Santa Monica
- - Vallejo
Florida
- - Miami
- - Ormond Beach
Illinois
- - Naperville
- - Wheaton
Indiana
- - Evansville
- - South Bend
Arkansas
- - Hot Springs
Connecticut
- - New Haven
Massachusetts
- - Boston
Michigan
- - Clinton Township
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2008-10-28 |
| Est. Completion | 2009-06-26 |
| Phase | Phase 2 |
What the finished NCT00778700 record still lists
NCT00778700 is an interventional study that assigns participants to a tested intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib Phosphate is the first listed.
NCT00778700 names 20 study sites across 14 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00778700 about?
NCT00778700 is a clinical study titled "A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis". The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive dressings. There were 4 treatment groups anticipated to have 50 participant...
What is the current status of trial NCT00778700?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2008-10-28. Estimated completion is 2009-06-26.
What conditions does trial NCT00778700 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00778700?
The interventions under investigation include: Ruxolitinib Phosphate (DRUG), Placebo Cream (OTHER).
Who is sponsoring clinical trial NCT00778700?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00778700 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00778700's enrollment target sits among peer trials
199 41st of 125 higher than 85 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04312126 · 199 participants
The Beneficial Effects of Naps on Motor Learning
- NCT04951622 · 199 participants · Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- NCT06474533 · 199 participants
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI